(Repeats to more subscribers)
BERLIN, Oct 12 (Reuters) - CureVac will withdraw
its first-generation COVID-19 vaccine candidate and focus on
collaborating with GSK to develop second-generation mRNA
vaccine technology instead, the Germany-based biotechnology
company said on Tuesday.
The company said it will withdraw its first-generation
vaccine candidate CVnCoV, which failed late-stage trials with
47% accuracy in June, due to a potential overlap with approval
timelines for a second-generation candidate.
The earliest potential approval of CVnCoV would have come in
the second quarter of 2022 when the candidates from the
second-generation vaccine program are expected to progress to
late-stage clinical development by that time, CureVac said.
(Reporting by Zuzanna Szymanska
Editing by Riham Alkousaa)
Glaxosmithkline (GSK)